Articles

Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo. Read More ›

Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established. Read More ›

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals. Read More ›

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity. Read More ›

A successful antibiotic stewardship intervention can reduce the usage of fluoroquinolones for patient safety and resistance concerns in community-acquired pneumonia. Read More ›

Investigators evaluated the in vitro activity of omadacycline, a novel aminomethylcycline antibiotic, against a collection of clinical isolates resistant to other available tetracyclines. Read More ›

When considering antibiotic-prescribing guidelines in the community setting, is “one size fits all” applicable in the face of emerging extended-spectrum cephalosporin-resistant Enterobacteriaceae? Read More ›

The efficacy of omadacycline was demonstrated in Gram-positive and Gram-negative clinical isolates from 3 completed phase 3 trials involving tetracycline nonsusceptible pathogens. Read More ›